Market Research Report - 241114
Injectable Antibodies: Products, Markets, Players and Forecasts
|Published by||Greystone Research Associates|
|Injectable Antibodies: Products, Markets, Players and Forecasts|
|Published: May 17, 2012||Content info:||
This publication has been discontinued on December 9, 2013.
Greystone Research Associates is pleased to announce the publication of a new market study. Injectable Antibodies: Products, Markets, Players and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for therapeutic antibodies administered via injection. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The administration of therapeutic antibodies via injection is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. The inherent instability of protein drugs has led to a number of challenges as the developers of injectable antibodies attempt to deal with packaging, handling, reconstitution and drug administration issues. These challenges are being compounded by the trend to patient self-medication, as population demographics and efforts by managed care providers to control healthcare costs drive the growth in drug self-administration, particularly for chronic conditions. This trend is introducing a new class of naive users to parenteral drug delivery. This report analyzes twenty-six injectable/Infusible therapeutic antibody drugs and examines key packaging, dosing, regulatory, economic and competitive factors that represent opportunities, risk factors and potential barriers to commercial success.